Hereditary angioedema: An update on available therapeutic options;Hereditäres Angioödem: Update zu verfügbaren Therapieoptionen

JDDG - Journal of the German Society of Dermatology

Volumn 8, Issue 9, 2010, Pages 663-673

  Maurer, Marcus ^a   Magerl, Markus ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

acute therapy; androgen derivatives; bradykinin; C1 INH; hereditary angioedema; icatibant; prophylaxis

Indexed keywords

ANTIFIBRINOLYTIC AGENT; BRADYKININ; BRADYKININ B2 RECEPTOR; COMPLEMENT COMPONENT C1S INHIBITOR; DANAZOL; ECALLANTIDE; ICATIBANT; KALLIKREIN; METHYLTESTOSTERONE; OXANDROLONE; STANOZOLOL; TRANEXAMIC ACID;

ANDROGEN THERAPY; ANGIONEUROTIC EDEMA; DOCUMENTATION; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; GERMANY; HUMAN; LACTATION; LONG TERM CARE; PREGNANCY; PROPHYLAXIS; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SHORT COURSE THERAPY; SURGICAL TECHNIQUE; THROMBOEMBOLISM; VISUAL IMPAIRMENT;

ANDROGENS; BRADYKININ; COMPLEMENT C1 INHIBITOR PROTEIN; DIAGNOSIS, DIFFERENTIAL; DRUGS, INVESTIGATIONAL; FEMALE; HEREDITARY ANGIOEDEMA TYPES I AND II; HUMANS; INFANT, NEWBORN; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LONG-TERM CARE; MALE; PREGNANCY; RECOMBINANT PROTEINS;

EID: 77956154246     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2010.07450.x     Document Type: Review

References (58)

1. Bracho FA. Hereditary angioedema. Curr Opin Hematol 2005 12 : 493 498.
2. Bork K, Staubach P, Eckardt AJ, Hardt J. Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency. Am J Gastroenterol 2006 101 : 619 627.
3. Agostoni A, Aygoren-Pursun E, Binkley KE, Blanch A, Bork K, Bouillet L, Bucher C, Castaldo AJ, Cicardi M, Davis AE, De CC, Drouet C, Duponchel C, Farkas H, Fay K, Fekete B, Fischer B, Fontana L, Fust G, Giacomelli R, Groner A, Hack CE, Harmat G, Jakenfelds J, Juers M, Kalmar L, Kaposi PN, Karadi I, Kitzinger A, Kollar T, Kreuz W, Lakatos P, Longhurst HJ, Lopez-Trascasa M, Martinez-Saguer I, Monnier N, Nagy I, Nemeth E, Nielsen EW, Nuijens JH, O'grady C, Pappalardo E, Penna V, Perricone C, Perricone R, Rauch U, Roche O, Rusicke E, Spath PJ, Szendei G, Takacs E, Tordai A, Truedsson L, Varga L, Visy B, Williams K, Zanichelli A, Zingale L. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 2004 114 : S51 131.
4. Longhurst HJ, Bork K. Hereditary angioedema: causes, manifestations and treatment. Br J Hosp Med (Lond) 2006 67 : 654 657.
5. HAEdb-C1 inhibitor gene mutation database. http://hae.enzim.hu/stat.php. 2008. 7-1-2010.
6. Gompels MM, Lock RJ, Abinun M, Bethune CA, Davies G, Grattan C, Fay AC, Longhurst HJ, Morrison L, Price A, Price M, Watters D. C1 inhibitor deficiency: consensus document. Clin Exp Immunol 2005 139 : 379 394.
7. Weiler CR, van Dellen RG. Genetic test indications and interpretations in patients with hereditary angioedema. Mayo Clin Proc 2006 81 : 958 972.
8. Bowen T, Cicardi M, Bork K, Zuraw B, Frank M, Ritchie B, Farkas H, Varga L, Zingale LC, Binkley K, Wagner E, Adomaitis P, Brosz K, Burnham J, Warrington R, Kalicinsky C, Mace S, McCusker C, Schellenberg R, Celeste L, Hebert J, Valentine K, Poon MC, Serushago B, Neurath D, Yang W, Lacuesta G, Issekutz A, Hamed A, Kamra P, Dean J, Kanani A, Stark D, Rivard GE, Leith E, Tsai E, Waserman S, Keith PK, Page D, Marchesin S, Longhurst HJ, Kreuz W, Rusicke E, Martinez-Saguer I, Aygoren-Pursun E, Harmat G, Fust G, Li H, Bouillet L, Caballero T, Moldovan D, Spath PJ, Smith-Foltz S, Nagy I, Nielsen EW, Bucher C, Nordenfelt P, Xiang ZY. Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Ann Allergy Asthma Immunol 2008 100 : S30 S40.
9. Nzeako UC, Frigas E, Tremaine WJ. Hereditary angioedema: a broad review for clinicians. Arch Intern Med 2001 161 : 2417 2429.
10. Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006 119 : 267 274.
11. Bas M, Adams V, Suvorava T, Niehues T, Hoffmann TK, Kojda G. Nonallergic angioedema: role of bradykinin. Allergy 2007 62 : 842 856.
12. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet 1998 351 : 1693 1697.
13. Nussberger J, Cugno M, Cicardi M, Agostoni A. Local bradykinin generation in hereditary angioedema. J Allergy Clin Immunol 1999 104 : 1321 1322.
14. Nussberger J, Cugno M, Cicardi M. Bradykinin-mediated angioedema. N Engl J Med 2002 347 : 621 622.
15. Davis AE. The pathophysiology of hereditary angioedema. Clin Immunol 2005 114 : 3 9.
16. Skidgel RA, Erdös EG. Histamine, Bradykinine and Their Antagonists. In: Goodmann & Gilman: The Pharmacological Basis of Therapeutics. 2005.
17. Bork K, Barnstedt SE, Koch P, Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 2000 356 : 213 217.
18. Maurer M, Grabbe J. Urticaria: its history-based diagnosis and etiologi-cally oriented treatment. Dtsch Arztebl Int 2008 105 : 458 466.
19. Maurer M, Metz M, Magerl M, Siebenhaar F, Staubach P. [Autoreactive urticaria and autoimmune urticaria]. Hautarzt 2004 55 : 350 356.
20. Magerl M, Maurer M. [Urticaria. "From bench to bedside"]. Hautarzt 2007 58 : 308 313.
21. Liekenbrocker T, Korner M, Kapp A, Elsner J. [Hereditary C1 esterase inhibitor deficiency type I. Divergence of clinical symptoms and laboratory chemical findings]. Hautarzt 2001 52 : 434 438.
22. Pruet CW, Kornblut AD, Brickman C, Kaliner MA, Frank MM. Management of the airway in patients with angioedema. Laryngoscope 1983 93 : 749 755.
23. Bork K, Meng G, Staubach P, Hardt J. Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion 2005 45 : 1774 1784.
24. Bork K, Staubach P, Hardt J. Treatment of skin swellings with C1-inhibitor concentrate in patients with hereditary angio-oedema. Allergy 2008 63 : 751 757.
25. Farkas H, Jakab L, Temesszentandrasi G, Visy B, Harmat G, Fust G, Szeplaki G, Fekete B, Karadi I, Varga L. Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy. J Allergy Clin Immunol 2007 120 : 941 947.
26. Craig TJ, Levy RJ, Wasserman RL, Bewtra AK, Hurewitz D, Obtulowicz K, Reshef A, Ritchie B, Moldovan D, Shirov T, Grivcheva-Panovska V, Kiessling PC, Keinecke HO, Bernstein JA. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 2009 124 : 801 808.
27. Craig T, Wassermann R, Levy R, Bewtra A, Hurewitz D, eters C, Kiessling P. C1 esterase inhibitor (C1-INH) - Standard of Care for the Treatment of Acute Attacks in Hereditary Angioedema (HAE): Initial Results of an Ongoing, Prospective, Open Label Study in North America (I.M.P.A.C.T.2). J Allergy Clin Immunol 2008 121 : S98 S99.
28. Fachinformation Berinert® P. 2009.
29. Bork K, Hardt J. Hereditary angioedema: increased number of attacks after frequent treatments with C1 inhibitor concentrate. Am J Med 2009 122 : 780 783.
30. Bork K, Frank J, Grundt B, Schlattmann P, Nussberger J, Kreuz W. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol 2007 119 : 1497 1503.
31. CHMP ASSESSMENT REPORT FOR Firazyr. http://www.emea.europa.eu/humandocs/ PDFs/EPAR/firazyr/H-899-en6. 2008. 7-1-2010.
32. Fachinformation Firazyr®. 2009.
33. Krause K, Metz M, Zuberbier T, Maurer M, Magerl M. Successful treatment of hereditary angioedema with bradykinin B2-receptor antagonist icatibant. J Dtsch Dermatol Ges 2010 8 : 272 274.
34. Choi G, Soeters MR, Farkas H, Varga L, Obtulowicz K, Bilo B, Porebski G, Hack CE, Verdonk R, Nuijens J, Levi M. Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. Transfusion 2007 47 : 1028 1032.
35. REFUSAL CHMP ASSESSMENT REPORT FOR RHUCIN. http://www.emea.europa.eu/ humandocs/Humans/EPAR/rhucin/rhucinR.htm. 2008. 7-1-2010.
36. Zuraw BL, Christiansen SC. New promise and hope for treating hereditary angioedema. Expert Opin Investig Drugs 2008 17 : 697 706.
37. Marques L, Domingo D, Maravall FJ, Clotet J. Short-term prophylactic treatment of hereditary angioedema with icatibant. Allergy 2010 65 : 137 138.
38. Craig T, Riedl M, Dykewicz MS, Gower RG, Baker J, Edelman FJ, Hurewitz D, Jacobs J, Kalfus I. When is prophylaxis for hereditary angioedema necessary? Ann Allergy Asthma Immunol 2009 102 : 366 372.
39. Banerji A, Sloane DE, Sheffer AL. Hereditary angioedema: a current state-of-the-art review, V: attenuated andro-gens for the treatment of hereditary angioedema. Ann Allergy Asthma Immunol 2008 100 : S19 S22.
40. Agostoni A, Cicardi M, Martignoni GC, Bergamaschini L, Marasini B. Danazol and stanozolol in long-term prophylactic treatment of hereditary angioedema. J Allergy Clin Immunol 1980 65 : 75 9.
41. Warin AP, Greaves MW, Gatecliff M, Williamson DM, Warin RP. Treatment of hereditary angiooedema by low dose attenuated androgens: disassociation of clinical response from levels of C1 esterase inhibitor and C4. Br J Dermatol 1980 103 : 405 409.
42. Hosea SW, Santaella ML, Brown EJ, Berger M, Katusha K, Frank MM. Long-term therapy of hereditary angioedema with danazol. Ann Intern Med 1980 93 : 809 812.
43. Cicardi M, Bergamaschini L, Cugno M, Hack E, Agostoni G, Agostoni A. Long-term treatment of hereditary angioedema with attenuated androgens: a survey of a 13-year experience. J Allergy Clin Immunol 1991 87 : 768 773.
44. Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol 2008 100 : 153 161.
45. Meeks ML, Mahaffey KW, Katz MD. Danazol increases the anticoagulant effect of warfarin. Ann Pharmacother 1992 26 : 641 642.
46. Zielinski JJ, Lichten EM, Haidukewych D. Clinically significant danazol-carbamazepine interaction. Ther Drug Monit 1987 9 : 24 7.
47. Matalliotakis I, Panidis D, Vlassis G, Neonaki M, Koumantakis E. Decreased sensitivity to insulin during treatment with danazol in women with endome-triosis. Clin Exp Obstet Gynecol 1997 24 : 160 162.
48. Arzneimittelgesetz. http://www.gesetze-im-internet.de/amg-1976/index. html. 2009. 7-1-2010.
49. Zuraw BL. Hereditary angiodema: a current state-of-the-art review, IV: short- and long-term treatment of hereditary angioedema: out with the old and in with the new? Ann Allergy Asthma Immunol 2008 100 : S13 S18.
50. Kreuz W, Martinez-Saguer I, Aygoren-Pursun E, Rusicke E, Heller C, Klingebiel T. C1-inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis. Transfusion 2009 49 : 1987 1995.
51. Westaby D, Ogle SJ, Paradinas FJ, Randell JB, Murray-Lyon IM. Liver damage from long-term methyltesto-sterone. Lancet 1977 2 : 262 263.
52. Balasch J, Martinez-Roman S, Carreras J, Vanrell JA. Acute pancreatitis associated with danazol treatment for endo-metriosis. Hum Reprod 1994 9 : 1163 1165.
53. Chevalier X, Awada H, Baetz A, Amor B. Danazol induced pancreatitis and hepatitis. Clin Rheumatol 1990 9 : 239 241.
54. Bork K, Pitton M, Harten P, Koch P. Hepatocellular adenomas in patients taking danazol for hereditary angiooedema. Lancet 1999 353 : 1066 1067.
55. Guess HA. Benign prostatic hyperplasia and prostate cancer. Epidemiol Rev 2001 23 : 152 158.
56. Szeplaki G, Varga L, Valentin S, Kleiber M, Karadi I, Romics L, Fust G, Farkas H. Adverse effects of danazol prophylaxis on the lipid profiles of patients with hereditary angioedema. J Allergy Clin Immunol 2005 115 : 864 869.
57. Szegedi R, Szeplaki G, Varga L, Prohaszka Z, Szeplaki Z, Karadi I, Fust G, Farkas H. Long-term danazol prophylaxis does not lead to increased carotid intimamedia thickness in hereditary angioedema patients. Atherosclerosis 2008 198 : 184 191.
58. Birjmohun RS, Kees HG, Stroes ES, Hofstra JJ, Dallinga-Thie GM, Mei-jers JC, Kastelein JJ, Levi M. Effects of short-term and long-term danazol treatment on lipoproteins, coagulation, and progression of atherosclerosis: two clinical trials in healthy volunteers and patients with hereditary angioedema. Clin Ther 2008 30 : 2314 2323.